Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Abeona TherapeuticsEnlivex TherapeuticsMustang BioNovanOncternal Therapeutics
SymbolNASDAQ:ABEONASDAQ:ENLVNASDAQ:MBIONASDAQ:NOVNNASDAQ:ONCT
Price Information
Current Price$1.49$10.97$3.05$1.10$6.48
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.41.61.61.7
Analysis Score3.43.53.53.54.5
Community Score3.03.42.42.23.3
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.71.70.0
Earnings & Valuation Score0.60.00.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$5.17$33.00$11.00$1.50$15.20
% Upside from Price Target246.76% upside200.82% upside260.66% upside36.36% upside134.57% upside
Trade Information
Market Cap$147.57 million$172.89 million$259.78 million$166.82 million$319.88 million
Beta1.691.141.850.011.66
Average Volume3,822,273416,2402,881,02115,354,1781,721,135
Sales & Book Value
Annual Revenue$3 millionN/AN/A$4.90 million$2.42 million
Price / Sales49.19N/AN/A34.04132.18
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.13 per share$1.09 per share$1.25 per share($0.89) per share$0.93 per share
Price / Book0.70N/AN/A-1.246.97
Profitability
Net Income$-76,280,000.00$-9,380,000.00$-46,390,000.00$-30,640,000.00$-34,190,000.00
EPS($1.51)($1.11)($1.29)($0.80)($1.56)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-379.35%-746.10%
Return on Equity (ROE)-37.97%-34.60%-90.84%N/A-150.58%
Return on Assets (ROA)-28.76%-28.47%-68.47%-43.81%-91.87%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.02%N/A0.11%N/A
Current Ratio2.70%7.23%9.91%5.56%3.01%
Quick Ratio2.70%7.23%9.91%5.56%3.01%
Ownership Information
Institutional Ownership Percentage36.47%2.39%25.75%6.23%10.79%
Insider Ownership Percentage19.10%N/A3.39%3.00%10.90%
Miscellaneous
EmployeesN/A36512412
Shares Outstanding99.04 million15.76 million85.18 million151.65 million49.36 million
Next Earnings Date5/5/2021 (Estimated)5/17/2021 (Estimated)5/10/2021 (Estimated)5/19/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Oncternal Therapeutics (NASDAQ:ONCT) Given "Buy" Rating at HC WainwrightOncternal Therapeutics (NASDAQ:ONCT) Given "Buy" Rating at HC Wainwright
americanbankingnews.com - April 17 at 2:09 PM
Oncternal Therapeutics Inc. [ONCT] moved down -18.16: Why It’s ImportantOncternal Therapeutics Inc. [ONCT] moved down -18.16: Why It’s Important
dbtnews.com - April 13 at 9:01 PM
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by OppenheimerOncternal Therapeutics (NASDAQ:ONCT) Now Covered by Oppenheimer
americanbankingnews.com - April 13 at 5:30 PM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Analysis: Is It The One You’re Looking For?Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Analysis: Is It The One You’re Looking For?
stocksregister.com - April 12 at 6:53 PM
Oncternal Therapeutics (ONCT) Received its Third Buy in a RowOncternal Therapeutics (ONCT) Received its Third Buy in a Row
smarteranalyst.com - April 12 at 1:50 PM
Why should you add Oncternal Therapeutics, Inc. (ONCT) to your portfolio?Why should you add Oncternal Therapeutics, Inc. (ONCT) to your portfolio?
marketingsentinel.com - April 12 at 8:49 AM
Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual MeetingOncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting
finance.yahoo.com - April 12 at 8:49 AM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Expected to Post Quarterly Sales of $1.11 MillionOncternal Therapeutics, Inc. (NASDAQ:ONCT) Expected to Post Quarterly Sales of $1.11 Million
americanbankingnews.com - April 12 at 3:44 AM
-$0.10 EPS Expected for Oncternal Therapeutics, Inc. (NASDAQ:ONCT) This Quarter-$0.10 EPS Expected for Oncternal Therapeutics, Inc. (NASDAQ:ONCT) This Quarter
americanbankingnews.com - April 10 at 8:24 AM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Forecasted to Post Q1 2021 Earnings of ($0.11) Per ShareOncternal Therapeutics, Inc. (NASDAQ:ONCT) Forecasted to Post Q1 2021 Earnings of ($0.11) Per Share
americanbankingnews.com - April 9 at 8:00 AM
Oncternal Therapeutics (ONCT) Soars 8.4%: Is Further Upside Left in the Stock?Oncternal Therapeutics (ONCT) Soars 8.4%: Is Further Upside Left in the Stock?
finance.yahoo.com - April 8 at 8:58 AM
Investors Purchase Large Volume of Call Options on Oncternal Therapeutics (NASDAQ:ONCT)Investors Purchase Large Volume of Call Options on Oncternal Therapeutics (NASDAQ:ONCT)
americanbankingnews.com - April 7 at 11:18 PM
Why Oncternal Therapeutics Stock Is Popping TodayWhy Oncternal Therapeutics Stock Is Popping Today
nasdaq.com - April 7 at 6:47 PM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Given Average Recommendation of "Buy" by BrokeragesOncternal Therapeutics, Inc. (NASDAQ:ONCT) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 6 at 6:24 PM
Implied Volatility Surging for Oncternal Therapeutics (ONCT) Stock OptionsImplied Volatility Surging for Oncternal Therapeutics (ONCT) Stock Options
finance.yahoo.com - April 5 at 12:10 PM
Brookline Capital Management Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)Brookline Capital Management Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)
americanbankingnews.com - March 30 at 4:24 PM
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT) and I-MAB (IMAB)Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT) and I-MAB (IMAB)
smarteranalyst.com - March 30 at 4:21 PM
Brookline Capital Acquisition Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)Brookline Capital Acquisition Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)
americanbankingnews.com - March 30 at 11:34 AM
Short Interest in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Expands By 136.6%Short Interest in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Expands By 136.6%
americanbankingnews.com - March 29 at 7:20 AM
Oncternal Therapeutics Inc. [ONCT] gain 49.39% so far this year. What now?Oncternal Therapeutics Inc. [ONCT] gain 49.39% so far this year. What now?
dbtnews.com - March 25 at 2:45 PM
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Projected to Grow by 186.89% Or MoreOncternal Therapeutics, Inc. (NASDAQ:ONCT) Projected to Grow by 186.89% Or More
marketingsentinel.com - March 25 at 9:44 AM
Oncternal Therapeutics (NASDAQ:ONCT) Cut to Hold at Zacks Investment ResearchOncternal Therapeutics (NASDAQ:ONCT) Cut to Hold at Zacks Investment Research
marketbeat.com - March 20 at 3:15 AM
Oncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Call TranscriptOncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Call Transcript
nasdaq.com - March 19 at 5:37 PM
Analyzing The Price Action In Oncternal Therapeutics Stock TodayAnalyzing The Price Action In Oncternal Therapeutics Stock Today
msn.com - March 17 at 3:27 PM
Were Not Very Worried About Oncternal Therapeutics (NASDAQ:ONCT) Cash Burn RateWe're Not Very Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
finance.yahoo.com - March 15 at 2:29 PM
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Raises Price Target to $9HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Raises Price Target to $9
benzinga.com - March 12 at 8:33 PM
DateCompanyBrokerageAction
4/14/2021Abeona TherapeuticsHC WainwrightReiterated Rating
3/29/2021Abeona TherapeuticsSVB LeerinkReiterated Rating
11/11/2020Abeona TherapeuticsB. RileyReiterated Rating
11/10/2020Abeona TherapeuticsCantor FitzgeraldUpgrade
5/8/2020Abeona TherapeuticsRoyal Bank of CanadaLower Price Target
5/7/2020Abeona TherapeuticsMizuhoReiterated Rating
8/11/2020Mustang BioOppenheimerReiterated Rating
1/5/2020NovanPiper Jaffray CompaniesDowngrade
3/29/2019NovanJMP SecuritiesDowngrade
3/30/2021Oncternal TherapeuticsBrookline Capital ManagementReiterated Rating
3/30/2021Oncternal TherapeuticsBrookline Capital AcquisitionInitiated Coverage
2/23/2021Oncternal TherapeuticsNorthland SecuritiesInitiated Coverage
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.